TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06010251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS and bodily illusions
Description: Participants will be required to perform (in person) 10 interventions over a time frame of 2-4 weeks. They can perform this everyday or for a minimum of 2-3 times per week over 4 weeks.~Two types of illusions will be used 15 min each, the rubber hand illusion and the walking illusion to target upper and lower limbs. These procedures will impact the body representation of the participants resulting in bodily illusions.
Study: NCT06108947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin discontinuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin discontinuation
Study: NCT06563869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-GSF
Description: Polyethylene glycolylated recombinant human granulocyte stimulating factor （6mg）will be given 24 hours after the end of chemotherapy.
Study: NCT04776109

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block
Description: Bilateral erector spinae catheters will be placed at T8 level. an ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the back muscles and the transverse Processes. Next, 2-3 ml of 2% lidocaine will be infiltrated .~A 16-G, 8-cm Tuohy needle will be then introduced medially in the plane of the ultrasound beam and directed towards the transverse process. Once the needle is underneath the anterior fascia of the erector spinae muscle, 10 ml of saline 0.9% will be injected lifting the muscle of the transverse process. A catheter will be inserted into the newly formed space underneath the ES muscle and secured. The procedure will be repeated on the contralateral side. bupivacaine (20 ml of bupivacaine 0.25%) solution will be injected immediately into each catheter then infusion of bupivacaine 0.125% 0.1 ml/kg/h will be continued for 48 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block
Description: Bilateral erector spinae catheters will be placed at T8 level. an ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the back muscles and the transverse Processes. Next, 2-3 ml of 2% lidocaine will be infiltrated .~A 16-G, 8-cm Tuohy needle will be then introduced medially in the plane of the ultrasound beam and directed towards the transverse process. Once the needle is underneath the anterior fascia of the erector spinae muscle, 10 ml of saline 0.9% will be injected lifting the muscle of the transverse process. A catheter will be inserted into the newly formed space underneath the ES muscle and secured. The procedure will be repeated on the contralateral side. bupivacaine (20 ml of bupivacaine 0.25%) solution will be injected immediately into each catheter then infusion of bupivacaine 0.125% 0.1 ml/kg/h will be continued for 48 hours.
Study: NCT06021197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDAE
Description: Use of an NMDA enhancer for the treatment of CIAS
Study: NCT06141213

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound screening
Description: Ultrasound screening for fetal membrane thickness at 18-24 weeks of pregnancy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound screening
Description: Ultrasound screening for fetal membrane thickness at 18-24 weeks of pregnancy.
Study: NCT06182072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProAgio Dose Levels (DL) 1,2,3,4
Description: ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProAgio Dose Levels (DL) 1,2,3,4
Description: ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, nab paclitaxel
Description: ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, nab paclitaxel
Description: ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.
Study: NCT06021197

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cap
Description: Use of placebo as a comparator
Study: NCT06059898

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GBR surgery including membrane placement
Description: After the application of local anesthesia, an incision of the mucosa will be performed and the flap will be elevated. The flap closure line should not be directly over the defect, but away from the defect site to prevent wound dehiscence. The bony defect will be thoroughly cleaned and, in some cases, activated by drilling small holes in the cortical bone to increase blood flow into the bone graft. Bone substitute will be inserted, the membrane will be adapted and fixed, and the flap will be sutured

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GBR surgery including membrane placement
Description: After the application of local anesthesia, an incision of the mucosa will be performed and the flap will be elevated. The flap closure line should not be directly over the defect, but away from the defect site to prevent wound dehiscence. The bony defect will be thoroughly cleaned and, in some cases, activated by drilling small holes in the cortical bone to increase blood flow into the bone graft. Bone substitute will be inserted, the membrane will be adapted and fixed, and the flap will be sutured

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: After a healing period of 6 months, at the implantation site, a biopsy is taken from the site of dental implant insertion for further analysis of bone regeneration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: After a healing period of 6 months, at the implantation site, a biopsy is taken from the site of dental implant insertion for further analysis of bone regeneration
Study: NCT05799170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regional trauma care
Description: Study intervention is the establishment of in-hospital trauma treatment centers and the formation of regional trauma care system. Regional trauma care system refers to both the establishment of unified and standardized pre-hospital and in-hospital trauma triage and injury classification warning mechanism and the development of unified trauma treatment process and standard in a main government district (population within 1 million), with secondary general hospitals and above that have strong treatment capability as the trauma treatment centers. Regional trauma care system will strengthen both pre-hospital emergency care and in-hospital emergency treatment while reinforcing the information exchange between in-hospital emergency treatment and specialized treatment. Taking 5 to 6 hospitals with certain trauma treatment capacity as the trauma treatment point, the trauma treatment network is formed relying on the treatment point hospitals within the range of one trauma treatment center.
Study: NCT05333016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal exercise
Description: Multimodal exercise programming including aerobic, resistance, balance, and flexibility exercises
Study: NCT06025825

Intervention type: DRUG
Intervention: Articaine Hydrochloride + Epinephrine
Description: Buccal infiltration anesthesia + palatal infiltration anesthesia (with articaine HCl) was applied for first group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction.~Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction.

Intervention type: DRUG
Intervention: Articaine Hydrochloride + Epinephrine
Description: Buccal infiltration anesthesia + palatal infiltration anesthesia (with articaine HCl) was applied for first group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction.~Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction.

Intervention type: DRUG
Intervention: Articaine Hydrochloride + Epinephrine
Description: Buccal infiltration anesthesia + palatal infiltration anesthesia (with articaine HCl) was applied for first group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction.~Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction.

Intervention type: DRUG
Intervention: Lidocaine Hydrochloride + Epinephrine
Description: Buccal infiltration anesthesia + palatal infiltration anesthesia (with lidocaine HCl) was applied for second group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction for fourth group Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction for sixth group

Intervention type: DRUG
Intervention: Lidocaine Hydrochloride + Epinephrine
Description: Buccal infiltration anesthesia + palatal infiltration anesthesia (with lidocaine HCl) was applied for second group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction for fourth group Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction for sixth group

Intervention type: DRUG
Intervention: Lidocaine Hydrochloride + Epinephrine
Description: Buccal infiltration anesthesia + palatal infiltration anesthesia (with lidocaine HCl) was applied for second group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction for fourth group Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction for sixth group
Study: NCT05043987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO102
Description: Anti-claudin 18.2 Antibody-MMAE Drug Conjugate
Study: NCT03801590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crosslinking with Riboflavin and UV-A
Description: the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea.
Study: NCT05793502

Intervention type: DEVICE
Intervention: Solia S and Selectra 3D Developed by BIOTRONIK
Description: LBBaP with Solia S and Selectra 3D Developed by BIOTRONIK
Study: NCT06146712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asutra's 'Dream the night away' nighttime lotion
Description: Product contains Water (Aqua), Magnesium Chloride, Dimethyl Sulfone (MSM), Prunus Amygdalus Dulcis (Sweet Almond) Oil, Butyrospermum Parkii (Shea Butter), Sodium Lactate, Cetearyl Alcohol, Glyceryl Stearate Citrate, Glycerin, Undecane, Cetyl Palmitate, Polyglyceryl-3 Diisostearate, Pentylene Glycol, Glyceryl Stearate, Magnesium Sulfate, Melatonin, Tridecane, Potassium Chloride, Sodium Chloride, Calcium Chloride, Tocopheryl Acetate, Xanthan Gum, Hydroxyacetophenone, Sodium Hydroxide, Cymbopogon Flexuosus (East-Indian Lemongrass) Oil, Citral, Geraniol, Linalool
Study: NCT05043987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO102
Description: Anti-claudin 18.2 Antibody-MMAE Drug Conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO102
Description: Anti-claudin 18.2 Antibody-MMAE Drug Conjugate
Study: NCT06549517

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: MTT24.5 consists in the learning of 40 new datas or knowledges, along 24.5 hours distributted on classes or sessions, during which an average of 3.5 new pieces of knowledge are taught and reinforced through training. Participants are trained using 4 techniques assigned to each new piece of information from a total of 100 available techniques. These techniques include the use of non-dominant skills, literacy in Braille for sighted individuals, and performing 5 actions simultaneously. Each technique is designed to aid in the memorization and learning of new knowledge
Study: NCT04747795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: IV
Study: NCT05111886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Skills Training
Description: The training will focus on communication skills based on key constructs in the Health Belief Model and motivation/resistance research (described in section A3), the training will focus on: (1) conveying the benefits of parenting programs, (2) knowledge of and responses to common perceived barriers to attending parenting programs, and (3) skills and strategies to effectively motivate and refer parents in ways that are least likely to elicit resistance. The in-person training will last 60-90 minutes. It will include a theoretical background and experiential learning; each step of the referral process will be demonstrated and role-played. The investigators will work to ensure that personnel receive continuing education credits for the training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth GenPMTO
Description: The GenPMTO is delivered over the phone (not online). This version is up to 6 sessions in length. This brief eHealth version of GenPMTO will be delivered through community therapists. The program will be delivered one-on-one (i.e., between a therapist and a parent or couple).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Referral Process
Description: A written summary and process map of the referral process, modeled on the Institute for Healthcare Improvement (IHI) 9-step process for closing the loop on referrals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One Session Education about Resources
Description: One online or phone conversation with the therapist in which the therapist guides the parent to the following resources: (a) a book, Raising Cooperative Kids, by GenPMTO co-developer Marion Forgatch; (b) a website, behaviorchecker.org, which includes behavioral prescriptions for common behavior issues; and (c) information about Early Childhood and Family Education classes, which are provided for free in Minnesota through public schools.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Survey of Experience
Description: Satisfaction with referral process

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Survey of Experience
Description: Satisfaction with referral process

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Survey of Experience
Description: Satisfaction with referral process
Study: NCT05736614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1 Strength Based Case Management (SBCM) Condition
Description: Intervention participants will receive a trained SBCM to motivate, support, and assist in linkage to PrEP prescribers to help facilitate obtaining PrEP medication to initiate treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 2 PrEPare for Work Intervention Condition
Description: Intervention participants will receive 1-on-1 adherence counseling and personalized daily text messaging reminders to increase PrEP adherence. Intervention participants will undergo three adherence intervention sessions (once per week for 3 weeks) with interventionist.
Study: NCT05335629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10Mg Tab
Description: Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor) which is a new class of hypoglycemic drugs, and they can block sodium-dependent glucose transporter-2 (SGLT2) located in the early proximal renal tubule to increase urinary glucose excretion and decrease the concentration of blood glucose
Study: NCT05612711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: All participants will take both dronabinol and placebo at different points in the study in this crossover design trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: All participants will take both dronabinol and placebo at different points in the study in this crossover design trial.
Study: NCT05176743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfer (UCT)
Description: The UCT consists of three $100 VISA merchandise cards provided monthly via mail to participants randomized to the intervention arm. Merchandise cards can be used anywhere that VISA is accepted. Participants in the UCT arm will also receive Usual Care, including referral to the patient support services team and nutritional pamphlets.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unconditional Cash Transfer (UCT)
Description: The UCT consists of three $100 VISA merchandise cards provided monthly via mail to participants randomized to the intervention arm. Merchandise cards can be used anywhere that VISA is accepted. Participants in the UCT arm will also receive Usual Care, including referral to the patient support services team and nutritional pamphlets.
Study: NCT05274737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel sling
Description: The novel sling was designed and created by the principal investigator to address these concerns of the traditional slings that are currently available for postsurgical protection and immobilization after shoulder surgery. It is anticipated that the novel sling will allow the patient to be more active and more comfortable while still providing a safe healing environment after a shoulder injury or shoulder surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional abduction sling
Description: An abduction sling is the most common type of sling utilized to protect patients after rotator cuff surgery and total shoulder of arthroplasty and can be considered the current standard of care.
Study: NCT06409715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Care with PMRT and Acupressure
Description: Progressive Muscle Relaxation Training (PMRT) is a structured strategy created to reduce psychological and physiological stress by alternating muscle contraction and relaxation.Rooted in traditional Chinese medicine's meridian theory, acupressure employs manipulative techniques on distinct acupoints to induce therapeutic effects 18. Targeting enhanced circulation, pain relief, muscle relaxation, and systemic regulation, acupressure's efficacy as both a preventive and therapeutic modality in complementary and alternative medicine is well-established

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Description: vital sign monitoring, positional support, dietary management, pain control, psychological support, functional training, and educational initiatives on health matters.
Study: NCT05131451

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point of Care Autonomous AI diabetic retinopathy exam
Description: Participants will get a point of care diabetic retinopathy eye exam using autonomous AI. Those that test positive will be referred to Eye Care Provider for dilated eye exam.
Study: NCT04575857

Intervention type: DRUG
Intervention: Atorvastatin
Description: Participants in the intervention arm will receive a pill packet with atorvastatin (40mg) x 18 months.

Intervention type: DRUG
Intervention: Placebo
Description: Participants in the control arm will receive a pill packet with placebo x 18 months.
Study: NCT05899088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindful Movement
Description: Mindful Movement Program with Researcher Follow-up
Study: NCT05024201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THERAPEUTİC TOUCH FOR HEMODİALYSİS PATİENTS
Description: Therapeutic touch was applied to hemodialysis patients for 3 days every other day.
Study: NCT04165473

Intervention type: BEHAVIORAL
Intervention: Training Program for Developing Social- and Personal Resources
Description: The training-method shows how one's own resonance can be exposed in order to live the balance between one's own needs and those of others.~Living one's own resonance means: more quality of life, work-life balance, holistic health through living feelings and talents, live equal, respectful and loving relationships, more personal responsibility, authentic decision making find new role models in private and professional areas.~The teaching and learning methods of the trainings and seminars are implemented according to the latest state of brain research and enable new perspectives with regard to new learning strategies, goals, enthusiasm and motivation.~With the Kutschera-Resonanz® method we teach and learn to consciously use this unconscious reservoir so that completely new dimensions in thinking and acting open up.~In this training program the basic tools of communication and interaction according to the Kutschera-Resonanz® method are taught and experienced by the participants.
Study: NCT04335032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid gastro-resistant capsules
Description: same as in arm/group description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: same as in arm/group description
Study: NCT05660226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (telemonitoring)
Description: Using a digital mobile phone based telemonitoring platform to A: monitor patients and adjust their treatment accordingly based on the remote monitoring outcomes and B: provide E-Coaching/self learning modules (lifestyle)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard outpatient blood pressure management
Study: NCT04442412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (Cholecalciferol)
Description: patients in the Experimental arm (Arm B) will receive also a prephase therapy with VitD and a supplementation of VitD during the intere period of immunochemotherapy according to a prefixed schedule. Choice of type of immunochemotherapy will not rely on Comprehensive Geriatric Assessment (CGA) result, but treatment at reduced doses with R-miniCHOP is highly recommended option for UNFIT and FRAIL patients.

Intervention type: DRUG
Group type: OTHER
Intervention: RCHOP o R-miniCHOP at standard doses
Description: Patients on both arms receive pre-treatment with prednisone oral before 6 cycles of 21 days each of immunochemotherapy with RCHOP~o R-miniCHOP at standard doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCHOP o R-miniCHOP at standard doses
Description: Patients on both arms receive pre-treatment with prednisone oral before 6 cycles of 21 days each of immunochemotherapy with RCHOP~o R-miniCHOP at standard doses
Study: NCT04789499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline Powder
Description: Twice daily nasal irrigation with 400 mg theophylline capsules and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets dissolved in 240 ml of distilled water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Twice daily nasal irrigation with 500 mg lactose powder capsules and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets dissolved in 240 ml of distilled water.